project id: TCGA-TGCT; case submitter id: TCGA-YU-A90Y; source center: 23; state: released; a260 a280 ratio: 1.74; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.55; rna integrity number: 7.2; age at index: 23; days to birth: -8460; days to death: 17; ethnicity: not reported; gender: male; race: black or african american; vital status: Dead; year of birth: 1988; year of death: 2011; age at diagnosis: 8460; ajcc clinical m: M1b; ajcc clinical n: N3; ajcc clinical stage: Stage IIIC; ajcc pathologic stage: Stage IIIC; ajcc pathologic t: T3; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C62.90; igcccg stage: Poor Prognosis; last known disease status: not reported; morphology: 9070/3; primary diagnosis: Embryonal carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 908; days to sample procurement: 0; initial weight: 210.0; portion submitter id: TCGA-YU-A90Y-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 95.0; percent tumor nuclei: 85.0;